The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 49 | — | 20.1x | Near average | |
Growth | 69 | — | 5.6% | Above average | |
Quality | 98 | 457.8% | 7.6% | Above average | |
Safety | 25 | 0.3x | 0.4x | Below average | |
Capital Return | 87 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Elicio Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Elicio Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
ELTX stock shows a state of complete stability in analyst estimates across timeframes (Day, Week, Month), with the target price stabilizing at 17 dollars. This consistency reflects the absence of any recent revisions or catalysts that changed the perspective of the research institutions covering the stock, noting that coverage is currently limited to only one analyst, which eliminates any Dispersion in opinions.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.